Artrya (ASX:AYA) Notes Receivable: A$0.00 Mil (As of Dec. 2025)


ASX:AYA Artrya Ltd ASX:AYA
30 GF Score
Price A$5.91
! 1 Warning Sign
View Full Analysis

What is Artrya Notes Receivable?

Artrya ASX:AYA -3.11% 30 Notes Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:AYA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Artrya's Notes Receivable for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Artrya Notes Receivable Historical Data

* Premium members only.

The historical data trend for Artrya's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artrya Notes Receivable Chart

Artrya Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Notes Receivable
0.00 0.00 0.00 0.00 0.00

Artrya Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:AYA
30GF Score
Artrya Ltd ASX:AYA
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artrya Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of A$0.00 Mil mean?
Artrya (ASX:AYA) has a Notes Receivable of A$0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Artrya and its competitors.
Is Artrya's Notes Receivable too high?
Artrya's current Notes Receivable is A$0.00 Mil. Overall, Artrya has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Artrya's Notes Receivable compare to VEEV and BTSG?
Artrya's Notes Receivable of A$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Healthcare Providers & Services company?
A good Notes Receivable depends on the Healthcare Providers & Services industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Artrya and its competitors. Artrya's current Notes Receivable is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artrya stock overvalued right now?
Artrya (ASX:AYA) has a current Notes Receivable of A$0.00 Mil. The current Notes Receivable is A$0.00 Mil. Artrya's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Artrya (ASX:AYA), the current Notes Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artrya Business Description

Address 1257 Hay Street, West Perth, Perth, WA, AUS, 6005
Artrya Ltd is a medical technology company. The company is engaged in the development and commercialization of Artrya Salix, its patented artificial intelligence platform that detects, diagnoses, and helps address coronary artery disease. It is managed based on a single segment, being the development of AI-driven CCTA image analysis technology.
30GF Score

Get the complete analysis for ASX:AYA

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$5.91
Price